Zhang Chengyao, Wang Jiawu, Gu Haitao, Zhu Daihua, Li Yang, Zhu Peng, Wang Yaxu, Wang Jijian
Department of General Surgery, The Second Affiliated Hospital of Chongqing Medical University, Chongqing 400010, P.R. China.
Oncol Lett. 2012 Apr 1;3(4):831-838. doi: 10.3892/ol.2012.567. Epub 2012 Jan 16.
The aim of this study was to evaluate the curative effects and safety of capecitabine plus oxaliplatin compared with 5-fluorouracil (5-FU) plus oxaliplatin in patients with metastatic colorectal cancer (MCRC). We searched the Cochrane Central register of Controlled Trials (CENTRAL), PubMed, Ovid, ScienceDirect, EBSCO, EMBASE and conference proceedings for eligible trials. A meta-analysis was performed using Review Manager 5.0. A total of 3,603 cancer patients from 7 trials were analyzed, and the baseline patient characteristics were comparable in all studies. Curative effect outcomes including complete response (CR) (OR=0.78; 95% CI 0.47-1.31; p=0.35), partial response (PR) (OR=0.81; 95% CI 0.65-1.00; p=0.05) and the overall response rate (ORR) (OR=0.85; 95% CI 0.71-1.02; p=0.08) showed similar curative effects between the capecitabine plus oxaliplatin group and the 5-FU plus oxaliplatin group. Moreover, the median overall survival (OS) and progression-free survival (PFS) had no statistically significant differences. Regarding safety, hand-foot syndrome was more frequently observed in the capecitabine plus oxaliplatin group (OR=2.71; 95% CI 2.04-3.61; p<0.00001), while stomatitis and neutropenia were reversed. Other toxic effects had no statistically significant differences between the two groups. Our results showed that capecitabine plus oxaliplatin had similar curative effects to 5-FU plus oxaliplatin, however, it was safer in patients with MCRC.
本研究旨在评估卡培他滨联合奥沙利铂与5-氟尿嘧啶（5-FU）联合奥沙利铂治疗转移性结直肠癌（MCRC）患者的疗效和安全性。我们检索了Cochrane对照试验中心注册库（CENTRAL）、PubMed、Ovid、ScienceDirect、EBSCO、EMBASE以及会议论文集，以查找符合条件的试验。使用Review Manager 5.0进行荟萃分析。共分析了来自7项试验的3603例癌症患者，所有研究中患者的基线特征具有可比性。疗效结果包括完全缓解（CR）（比值比[OR]=0.78；95%置信区间[CI] 0.47-1.31；P=0.35）、部分缓解（PR）（OR=0.81；95% CI 0.65-1.00；P=0.05）和总缓解率（ORR）（OR=0.85；95% CI 0.71-1.02；P=0.08），结果显示卡培他滨联合奥沙利铂组与5-FU联合奥沙利铂组的疗效相似。此外，中位总生存期（OS）和无进展生存期（PFS）无统计学显著差异。在安全性方面，卡培他滨联合奥沙利铂组手足综合征的发生率更高（OR=2.71；95% CI 2.04-3.61；P<0.00001），而口腔炎和中性粒细胞减少症的情况则相反。两组之间的其他毒性作用无统计学显著差异。我们的结果表明，卡培他滨联合奥沙利铂与5-FU联合奥沙利铂疗效相似，但对MCRC患者更安全。
